Videos

Sevann Helo, MD, recaps an SMSNA 2025 session on setting patient boundaries.

Muhammed A. Moukhtar Hammad, MBBCh, outlines key findings from a study evaluating testosterone replacement therapy and hearing-related outcomes.

Michael J. Morris, MD, discusses the mechanism of action for AB001, PSMA-targeted radioligand therapy for patients with mCRPC.

Panelists discuss how IsoPSA improves diagnostic accuracy by targeting PSA protein structure, offering clearer insights for patient selection than concentration-based testing.

Panelists discuss how the gemcitabine-releasing system fits into the non–muscle-invasive bladder cancer (NMIBC) treatment algorithm by offering patients a promising intravesical option with excellent response rates and durability, though sequencing decisions must consider patient logistics, treatment availability, and individual preferences while potentially reducing but not eliminating the need for radical cystectomy.

This segment outlines how immune checkpoint inhibitors have become essential in bladder cancer management, examining their roles across treatment lines and the current standards of care.

Panelists discuss how structure-based biomarkers such as IsoPSA improve risk stratification by distinguishing aggressive disease from indolent cases more effectively than PSA level alone.

Landon Trost, MD, discusses patient-reported outcomes from a study comparing CCH treatment vs surgery for Peyronie's disease.

An expert discusses how the proposed Centers for Medicare & Medicaid Services (CMS) rule represents an unusual circumstance that benefits smaller private practices by reducing work relative value units (RVUs) while increasing practice expense and malpractice RVUs. This could potentially result in substantial reimbursement increases for prostatic urethral lift and water vapor therapy, which may enable earlier intervention in younger men who want to avoid more invasive surgeries and preserve bladder function long-term rather than relying on α-blockers that don’t prevent disease progression.

Aleece Fosnight, MSPAS, PA-C, highlights that although urinary leakage is common, it is not normal—and effective treatment options exist.

An expert discusses how the greatest unmet need in minimally invasive benign prostatic hyperplasia (BPH) treatments is achieving durability and retreatment rates that match those of surgical options such as transurethral resection of the prostate (TURP) while maintaining sexual function preservation. He also discusses how barriers to broader adoption include inadequate technical training in office-based procedures, ongoing reimbursement challenges, and poor patient awareness because many patients and even well-meaning primary care physicians are unaware of options beyond medications or TURP.

Krambeck highlights that FANS combine enhanced maneuverability and effective fragment evacuation, leading to higher stone clearance rates and improved procedural outcomes in endourology.

Ellen Cahill, MD, discusses a recent study on testosterone usage among men interested in fertility.

A. Lenore Ackerman, MD, PhD, discusses how clinicians should approach conversations with patients on the risks and benefits of vaginal estrogen.

Apolo highlighted the positive topline results from the phase 3 EV-303 trial (NCT03924895) evaluating EV plus pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer.

Veda N. Giri, MD, outlines alternative care delivery models that could help improve access to genetic testing for prostate cancer.

Panelists discuss how the SunRISe-1 trial demonstrated impressive efficacy with an 82% complete response rate and 26-month median duration of response in Bacillus Calmette-Guérin (BCG)-unresponsive patients, significantly outperforming other FDA-approved therapies while maintaining a favorable safety profile with mostly minor voiding symptoms and only 13% grade 3+ adverse events.

An expert discusses how the prostatic urethral lift procedural kit has transformed his practice economics from nearly having to stop offering the procedure due to low margins and Centers for Medicare & Medicaid Services (CMS) cuts to achieving the best margins seen in years. This has created what he calls a “rare triple win” that benefits urologists by maintaining procedure viability, patients by ensuring continued access to minimally invasive therapy with potentially more implants, and hospital systems through fewer re-treatments.

An expert discusses how his diagnostic treatment workflow for a new patient with benign prostatic hyperplasia (BPH) progresses from initial α-blocker therapy through noninvasive systematic testing with nurse practitioner review, followed by multichannel urodynamics, transrectal ultrasound, and cystoscopy if improvement is insufficient. He emphasizes that he pushes for a thorough evaluation even when symptoms seem mild because “the bladder is a notoriously unreliable witness,” and he wants to prevent emergency urinary retention by identifying underlying obstruction early.

Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, emphasized that many older patients eventually pursue care only after years of coping, when their quality of life has been significantly affected.

CAN-2409 plus valacyclovir significantly improved disease-free survival compared with placebo plus valacyclovir.

Findings showed that although most applicants emphasized work ethic and interpersonal skills, these attributes were not predictive of receiving an interview invitation.

A. Lenore Ackerman, MD, PhD, outlines the rationale for a guideline recommendation suggesting that D-mannose alone may not be effective for UTI prophylaxis.

Jack R. Andrews, MD; Alicia Morgans, MD, MPH; and Murilo de Almeida Luz, MD, discuss how ultralow prostate-specific antigen thresholds (below 0.02) serve as important prognostic biomarkers in metastatic hormone-sensitive prostate cancer, with recent post hoc analyses from the ARANOTE trial showing that patients achieving these ultralow levels with combination androgen deprivation therapy plus darolutamide therapy have significantly better radiographic progression-free survival and time to castration-resistant disease compared with those who don't reach these thresholds.

Jack R. Andrews, MD; Alicia Morgans, MD, MPH; and Murilo de Almeida Luz, MD, discuss how ultralow prostate-specific antigen thresholds (below 0.02) serve as important prognostic biomarkers in metastatic hormone-sensitive prostate cancer, with recent post hoc analyses from the ARANOTE trial showing that patients achieving these ultralow levels with combination androgen deprivation therapy plus darolutamide therapy have significantly better radiographic progression-free survival and time to castration-resistant disease compared with those who don't reach these thresholds.

Veda N. Giri, MD, outlines some of the key barriers to genetic testing in prostate cancer.

Melvin L.K. Chua, FRCR, PhD, FASCO, highlights data validating the performance of the ArteraAI Prostate test in an Asian cohort of patients with prostate cancer.

Chad A. Reichard, MD, outlines key findings from the CREST trial, evaluating the combination of sasanlimab plus BCG in patients with high-risk BCG-naïve NMIBC.

Shreyas S. Joshi, MD, MPH, discusses some of the key considerations for new agents entering the treatment landscape for BCG-unresponsive NMIBC.

Panelists discuss how the FDA-approved gemcitabine intravesical system (Inlexzo/TAR-200) represents a breakthrough in Bacillus Calmette-Guérin (BCG)-unresponsive bladder cancer treatment through its unique continuous drug delivery mechanism that provides sustained release over 3 weeks, requiring only 10% of traditional gemcitabine dosing while improving patient convenience and potentially reducing adverse effects.